Perceptive Advisors increased its stake in Praxis Precision Medicines by 431,432 shares (worth ~$80.34 million) in Q4 2025, bringing its total position to $588.30 million and making it the fund's largest holding at 10.8% of AUM. The biotech company's stock has surged 320% over the past year as it advances toward commercialization with two FDA NDAs submitted and a strong cash position of $1.547 billion.

Soleus Capital Management increased its stake in Celcuity by 629,398 shares, bringing its total holdings to over 1.8 million shares valued at $180.36 million. This purchase elevated Celcuity to Soleus's third-largest holding, representing 6.7% of the fund's AUM. The move signals bullish confidence in the clinical-stage biotech company, which has seen its stock surge 745% over the past year.

Praxis Precision Medicines announced strategic leadership changes to support its transition into late-stage development and commercial execution. The company appointed Jeffrey B. Kindler (former Pfizer CEO) and Stuart Arbuckle (former Vertex COO) to its board of directors, and promoted Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. These moves align with the company's focus on commercial launch planning, late-stage development, and strategic value optimization for its CNS disorder therapies.

Praxis Precision Medicines priced an underwritten public offering of 2.212 million shares at $260 per share, generating approximately $575 million in gross proceeds. The offering is expected to close on January 8, 2026, with underwriters granted a 30-day option to purchase an additional 331,800 shares. The company is a clinical-stage biopharmaceutical firm focused on CNS disorder therapies.

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, announced a proposed public offering of common stock and pre-funded warrants. The offering is being managed by Piper Sandler, TD Cowen, Guggenheim Securities, and Truist Securities as joint book-running managers, with completion subject to market conditions.

Praxis Precision Medicines stock surged 13.25% after receiving FDA Breakthrough Therapy Designation for ulixacaltamide, an experimental treatment for essential tremor. The designation, based on positive phase 3 study results, will accelerate the drug's development and regulatory review, with a New Drug Application planned for early 2026. Essential tremor affects approximately 7 million people in the U.S. with limited effective treatment options.

Praxis Precision Medicines received FDA Breakthrough Therapy Designation for ulixacaltamide, a T-type calcium channel inhibitor for essential tremor treatment, based on positive Phase 3 Essential3 program results. The company plans to submit a New Drug Application (NDA) in early 2026 following a successful pre-NDA meeting with the FDA.

Praxis Precision Medicines reported positive results from its EMBOLD study for SCN2A and SCN8A developmental and epileptic encephalopathies, leading to a significant stock price increase and potential FDA review.

Praxis Precision Medicines plans to raise approximately $525 million through a public offering of 3,025,480 common stock shares and pre-funded warrants at $157.00 per share, with underwriters including TD Cowen, Piper Sandler, Guggenheim Securities, and Truist Securities.

Law firm investigating Praxis Precision Medicines after reporting adverse events in mid-stage drug study, which caused stock price to drop 5.55%.

Praxis Precision Medicines will participate in a virtual fireside chat on September 2, 2025, discussing their latest research and data from the 36th International Epilepsy Consortium, focusing on CNS disorders and genetic epilepsies.

Law firm investigating potential securities law violations by Praxis Precision Medicines after reporting adverse events in mid-stage drug study, which caused stock price decline.